Abulus

AbulusAbulusAbulus

Abulus

AbulusAbulusAbulus
About
Technology
Pipelines
Contact

About US

Antibody delivery technology

Antibodies are the fastest growing area of new drug development. There are more than 70 approved antibodies and hundreds under clinical testing. However, antibody therapies are costly and can have adverse side effects. 


Abulus is a preclinical biotech company evaluating a proprietary antibody-based drug delivery platform that offers a cost-effective solution with increased efficacy and reduced adverse side effects.

Our mission

To significantly improve outcomes for patients undergoing antibody therapies by developing a better and more cost-effective drug delivery technology. 


The technology delivers antibodies accurately while extending the release time to disease sites for increased efficacy and reduced adverse side effects.


Technology

The antibody delivery technology is composed of a thermo-responsive biomaterial, immune tolerant elastin-like polypeptide (iTEP), which is safe, biocompatible, and does not induce an immune response.  

1. Universal

The iTEP delivery platform is applicable to any antibody and can deliver multiple antibodies simultaneously, allowing combinations of multiple antibodies to treat disease more efficiently.

2. ADJUSTABLE

The iTEP platform can adjust the release rates and ratios of the delivered antibodies to give optimal therapeutic efficacy while reducing side effects.

3. SimplE

The iTEP platform is a “plug-and- play” delivery platform that only needs a simple procedure of mixing iTEP and antibodies just ahead of injections, which takes only a few minutes. The iTEP platform maintains antibodies’ activity and integrity without chemically modifying antibodies. 

4. ScalabLE

The iTEP platform can be manufactured in large scale with high bench-to-bench consistency. The iTEP is prepared separately without involving any antibodies in its production and storage, which avoids the problem of instability or degradation of antibodies that occur in many current delivery platforms.

Pipelines

Previous preclinical research has demonstrated the safety and efficacy of the iTEP platform for antibody treatment. Three pipelines are to be explored in the future:

1. COMBINATORIAL immunotherapy for solid tumorS

Combinatorial immunotherapy is more effective than single-agent therapy in cancer patients. The iTEP platform can deliver multiple combinations of antibody-based immunotherapies to solid tumors and prevent the diffusion of antibodies to other healthy tissues, improving therapeutic effects and reducing the toxicity.

2. Local treatment for arthritis

Antibodies represent a significant market for the treatment of arthritis. The iTEP platform can retain therapeutic antibodies in joints for a prolonged period, more effectively relieving pain, inflammation, and other arthritis symptoms. 

3. Sustained release of antibodies

Nearly 40% of antibodies are given to patients through multiple and frequent subcutaneous injections. The iTEP platform can sustain the release of antibodies upon subcutaneous injection, reducing injection frequency and improving patient outcomes.

Contact Us

Send us a Message

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abulus, Inc.

Salt Lake City, Utah

(801) 414-5406

Hours

Monday - Friday: 9:00am - 5:00pm

Saturday - Sunday: Closed

Copyright © 2021 Abulus - All Rights Reserved.